Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$381 Mln
P/E Ratio
--
P/B Ratio
15.58
Industry P/E
--
Debt to Equity
0
ROE
-0.19 %
ROCE
-16.84 %
Div. Yield
0 %
Book Value
0.94
EPS
-0.15
CFO
$-48.68 Mln
EBITDA
$-60.10 Mln
Net Profit
$-84.02 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Eton Pharmaceuticals (ETON)
| 8.03 | -7.64 | 0.77 | 351.10 | 54.92 | 29.51 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
Eton Pharmaceuticals (ETON)
| 201.36 | 55.32 | -34.27 | -47.23 | 12.92 | 17.65 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 59.14 | 11,509.07 | 27.16 | 8.05 | |
| 62.71 | 7,341.95 | 56.58 | 23.56 | |
| 57.91 | 11,313.41 | 389.73 | 0.76 | |
| 7.58 | 8,928.80 | -- | -3.24 |
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, and commercializing pharmaceutical products for rare diseases. The company offers INCRELEX, treatment for children who suffer from severe primary insulin-like... growth factor 1 deficiency (SPIGFD); ALKINDI SPRINKLE, as a replacement therapy for Adrenocortical Insufficiency ("AI") in children under 17 years of age, and accurate dosing for newborns and children with AI; GALZIN, as a maintenance treatment for patients with Wilson Disease who have been initially treated with a chelating agent; PKU GOLIKE, medical formula for the dietary management of phenylketonuria ("PKU"); Carglumic Acid, treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase ("NAGS") deficiency; Betaine Anhydrous, for the treatment of homocystinuria; Nitisinone for the treatment of tyrosinemia type 1; and Amglidia for the treatment of neonatal diabetes mellitus products. It also develops ET-600 for the treatment of central diabetes insipidus; ET-700 for the treatment of treatment of Wilson disease; ET-800; Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois. Address: 21925 W. Field Parkway, Deer Park, IL, United States, 60010-7278 Read more
President, CEO & Director
Mr. Sean E. Brynjelsen
President, CEO & Director
Mr. Sean E. Brynjelsen
Headquarters
Deer Park, IL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Eton Pharmaceuticals Inc (ETON) stood at $ 76 Mln as on 31-Dec-24
The share price of Eton Pharmaceuticals Inc (ETON) is $14.39 (NASDAQ) as of 17-Apr-2025 13:39 EDT. Eton Pharmaceuticals Inc (ETON) has given a return of 54.92% in the last 3 years.
Eton Pharmaceuticals Inc (ETON) has a market capitalisation of $ 381 Mln as on 16-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Eton Pharmaceuticals Inc (ETON) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Eton Pharmaceuticals Inc (ETON) and enter the required number of quantities and click on buy to purchase the shares of Eton Pharmaceuticals Inc (ETON).
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, and commercializing pharmaceutical products for rare diseases. The company offers INCRELEX, treatment for children who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD); ALKINDI SPRINKLE, as a replacement therapy for Adrenocortical Insufficiency ("AI") in children under 17 years of age, and accurate dosing for newborns and children with AI; GALZIN, as a maintenance treatment for patients with Wilson Disease who have been initially treated with a chelating agent; PKU GOLIKE, medical formula for the dietary management of phenylketonuria ("PKU"); Carglumic Acid, treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase ("NAGS") deficiency; Betaine Anhydrous, for the treatment of homocystinuria; Nitisinone for the treatment of tyrosinemia type 1; and Amglidia for the treatment of neonatal diabetes mellitus products. It also develops ET-600 for the treatment of central diabetes insipidus; ET-700 for the treatment of treatment of Wilson disease; ET-800; Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois. Address: 21925 W. Field Parkway, Deer Park, IL, United States, 60010-7278
The CEO & director of Mr. Sean E. Brynjelsen. is Eton Pharmaceuticals Inc (ETON), and CFO & Sr. VP is Mr. Sean E. Brynjelsen.
There is no promoter pledging in Eton Pharmaceuticals Inc (ETON).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,140
|
|
|
1,139
|
|
|
930
|
|
|
770
|
| Eton Pharmaceuticals Inc. (ETON) | Ratios |
|---|---|
|
Return on equity(%)
|
-19.16
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-9.8
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Eton Pharmaceuticals Inc (ETON) was $0 Mln.
$0.31
(
